In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Jacquelyn A MyersDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jake D FriskeSt. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-8987-8538 Tabitha C McCartyDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
John J NavarroDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sarah RobinsonDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Rebecca L HalliburtonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-3196-123X Sandra J KietlinskaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Francisca N De Luna VitorinoDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-8543-2299 Baranda S HansenCenter for Advanced Genome Engineering, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-2299-650X Shondra M Pruett-MillerCenter for Advanced Genome Engineering, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-3793-585X Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-3596-4750 Martine F RousselSt. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-1740-8139 Charles W M RobertsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. charles.roberts@stjude.org.ORCID 0000-0003-1135-1896 Funding
Viral modulation of epitranscriptomic mechanismsR01AI118891 · NIAID · WASHINGTON UNIVERSITY · PI GARCIA, BENJAMIN A, WEITZMAN, MATTHEW D. · 2015 to 2025
$5.4MQuantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6MNIAID NIH HHS R01 AI118891NICHD NIH HHS R01 HD106051U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01-CA-196539U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HD-106051U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F31-CA-278355U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01-CA-96832U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA-113794U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA-172152U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA-273455
6 · The paper itselfAbstract
SWI/SNF chromatin remodeling complexes are perturbed in 20% of all cancers and in several developmental disorders, yet the mechanisms by which these mutations dysregulate transcription and drive disease are poorly understood. To both elucidate these mechanisms and identify vulnerabilities caused by these mutations, we leverage genome-wide CRISPR-Cas9 screening in hundreds of cancer cell lines and identify the chromatin reader protein PHIP as a specific dependency in cancers with broadly disrupted SWI/SNF function. Mechanistically, we reveal that PHIP cooperates with SWI/SNF to facilitate transcriptional activation by ubiquitinating and suppressing subunits of the repressive Nucleosome Remodeling and Deacetylase (NuRD) complex. We demonstrate that loss of SWI/SNF results in NuRD complexes accumulating at promoters where they would otherwise cause widespread transcriptional silencing if not antagonized by PHIP. Collectively, we identify PHIP as a regulator of the interplay between distinct chromatin regulators that function in development and disease and as a targetable vulnerability in cancers with broad SWI/SNF inactivation.
Indexed as
Chromosomal Proteins, Non-HistoneMi-2 Nucleosome Remodeling and Deacetylase ComplexNeoplasmsTranscription FactorsAnimalsCell Line, TumorChromatinChromatin Assembly and DisassemblyCRISPR-Cas SystemsDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansMutationPromoter Regions, GeneticTranscriptional ActivationUbiquitinationChromatinChromosomal Proteins, Non-HistoneDNA-Binding ProteinsMi-2 Nucleosome Remodeling and Deacetylase ComplexSWI-SNF-B chromatin-remodeling complexTranscription Factors
Identifiers
PMID41946722
PMCPMC13057301
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390